The ruling removes near-term downside risk to royalty rates and strengthens AnaptysBio’s negotiating and litigation position ahead of the July 2026 trial. Traders should monitor Jemperli sales trends and trial developments as catalysts for valuation re-rating, especially if reversion rights gain legal traction.
Price Chart
Executive Summary
AnaptysBio announced a favorable court ruling in its ongoing litigation with Tesaro/GSK, with the Delaware Chancery Court dismissing Tesaro’s claim of anticipatory breach and upholding the current royalty structure for Jemperli. The decision preserves AnaptysBio’s right to receive tiered royalties (up to 25%) and sets the stage for a July 2026 trial on Anaptys’ claims of material breach and reversion rights.
Key Facts
- Delaware Chancery Court dismissed Tesaro’s anticipatory breach claim against AnaptysBio.
- Court rejected Tesaro’s request to reduce royalty rates on Jemperli sales.
- Current royalty structure upheld: 8% below $1B, 12% between $1B–$1.5B, 20% between $1.5B–$2.5B, and 25% above $2.5B in annual net sales.
- Trial on AnaptysBio’s claims — including right to reversion of Jemperli — scheduled for July 14–17, 2026.
- Anaptys claims Tesaro breached exclusivity, diligence, and notice obligations under the Collaboration Agreement.
Financial Impact
Preserves potential royalty stream worth hundreds of millions of dollars; Jemperli sales were $1.2B in 2025 (implied from royalty tiers and public data). At current trajectory, Anaptys could receive ~$144M annually (12% of $1.2B), with upside to 20–25% as sales grow.
Risk Factors
- Final outcome of trial in July 2026 remains uncertain; reversion of Jemperli is not guaranteed.
- GSK/Tesaro may appeal or pursue further legal action.
- Royalty revenue dependent on continued commercial performance of Jemperli.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Institutional Cluster | $56.02 $53.87 | ▼ −3.84% | ▼ −2.09% | $48.53 (−13.37%) |
Jun 29, 2026 13w ago | 144 | $67.50 $53.61 | ▲ +20.58% | ▲ +19.55% | $48.53 (+28.10%) |
Jun 29, 2026 13w ago | DEFA14A | $67.50 $53.61 | ▼ −20.58% | ▼ −19.55% | $48.53 (−28.10%) |
Jun 26, 2026 14w ago | 144 | $65.97 $54.15 | ▲ +17.92% | ▲ +17.64% | $48.53 (+26.44%) |
Jun 22, 2026 14w ago | 8-K | $59.43 $50.29 | ▼ −15.38% | ▼ −16.54% | $48.53 (−18.34%) |
Jun 17, 2026 15w ago | 144 | $57.51 $54.15 | ▲ +5.84% | ▲ +6.38% | $48.53 (+15.61%) |
Jun 15, 2026 15w ago | 144 | $57.61 $62.51 | ▼ −8.51% | ▼ −8.31% | $48.53 (+15.76%) |
Jun 11, 2026 16w ago | 144 | $56.07 $66.39 | ▼ −18.41% | ▼ −16.63% | $48.53 (+13.45%) |
Jun 10, 2026 16w ago | 144 | $54.24 $66.59 | ▼ −22.77% | ▼ −20.88% | $48.53 (+10.53%) |
Jun 8, 2026 16w ago | 144 | $51.63 $67.33 | ▼ −30.40% | ▼ −28.95% | $48.53 (+6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access